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We have engineered polymer-based microenvironments that promote vasculogenesis both in vitro and
in vivo through synergistic integrin-growth factor receptor signalling. Poly(ethyl acrylate) (PEA) triggers
spontaneous organization of ﬁbronectin (FN) into nanonetworks which provide availability of critical
binding domains. Importantly, the growth factor binding (FNIII12-14) and integrin binding (FNIII9-10) re-
gions are simultaneously available on FN ﬁbrils assembled on PEA. This material platform promotes
synergistic integrin/VEGF signalling which is highly effective for vascularization events in vitro with low
concentrations of VEGF. VEGF speciﬁcally binds to FN ﬁbrils on PEA compared to control polymers
(poly(methyl acrylate), PMA) where FN remains in a globular conformation and integrin/GF binding
domains are not simultaneously available. The vasculogenic response of human endothelial cells seeded
on these synergistic interfaces (VEGF bound to FN assembled on PEA) was signiﬁcantly improved
compared to soluble administration of VEGF at higher doses. Early onset of VEGF signalling (PLCg1
phosphorylation) and both integrin and VEGF signalling (ERK1/2 phosphorylation) were increased only
when VEGF was bound to FN nanonetworks on PEA, while soluble VEGF did not inﬂuence early sig-
nalling. Experiments with mutant FN molecules with impaired integrin binding site (FN-RGE) conﬁrmed
the role of the integrin binding site of FN on the vasculogenic response via combined integrin/VEGF
signalling. In vivo experiments using 3D scaffolds coated with FN and VEGF implanted in the murine fat
pad demonstrated pro-vascularization signalling by enhanced formation of new tissue inside scaffold
pores. PEA-driven organization of FN promotes efﬁcient presentation of VEGF to promote vascularization
in regenerative medicine applications.
© 2017 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Fully developed vascular networks are essential for cell growth
and tissue formation as they aid nutrient and oxygen supply andsgow.ac.uk (M. Salmeron-
Ltd. This is an open access articleremoval of toxic metabolites [1]. Detailed understanding of the
process of vessel formation can provide a powerful tool to control
vascularization in pathological conditions, and it can prove useful in
tissue engineering and regenerative medicine where developing
functional vascularized tissue is still a major challenge [2].
New vessels can be formed in two distinct ways: either via
sprouting of existing vessels (angiogenesis), or development of de
novo vessels from progenitor cells (vasculogenesis). As these pro-
cesses are complex, a dynamic interaction between cells, growthunder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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strict temporal and spatial regulation to allow both a nascent tube
formation and vessel maturation [3]. Angioblasts derived from
bone marrow progenitor cells differentiate into endothelial cells
and together with smooth muscle cells go on to form the vessel [3].
The presence of other cell types such as pericytes is important for
vessel maturation [3]. A detailed role of secreted GFs and cytokines
orchestrating this process has still not been fully elucidated, how-
ever a prominent role for the vascular endothelial GF (VEGF) family
and their receptors and ﬁbroblastic GF (FGF) has been repeatedly
described [4,5]. Additionally, the complex ECM structure consisting
of proteins such as ﬁbrin, ﬁbronectin (FN), collagens, laminin and
others serve not only as a mechanical scaffold for cell migration,
proliferation and non-speciﬁc retention of GFs but create a dynamic
environment able to bind GFs speciﬁcally, forming gradients and
possibly releasing them on demand during proteolytic degradation
[6e9].
In vitro, there has been remarkable success in forming new
vessels using various microﬂuidic chambers to study the funda-
mentals of vasculogenesis [10,11]. However, it is challenging toFig. 1. Integrin-VEGF synergistic signalling triggered by FN organized into nanonetworks on
different polymer substrates; on PMA it remains in globular conformation, whereas on PEA,
VEGF bound to FN on cell signalling: the presentation of VEGF bound to FN in close vicinity
and integrins to work in synergy.translate these results to in vivo applications. Considerable research
closer to eventual in vivo applications has focused on engineering
different 3D environments (hydrogels, synthetic polymer matrices)
containing key GFs such as VEGF, FGF, platelet-derived GF (PDGF) or
insulin-like GF (IGF) and/or cell adhesion and ECM protein binding
motifs that support endogenous endothelial cell growth [8,12].
However, this approach generally requires quite high doses of GFs
and faces issues such as low GF stability and accessibility. Strategies
incorporating molecules able to sequester GFs are promising to
present GFs more efﬁciently and considerably reduce GF doses
needed for biological effects [12]. ECM proteins such as ﬁbrinogen
or FN, or their engineered fragments, have been utilized to bind and
present bonemorphogenetic protein 2 (BMP-2), PDGF, or VEGF, and
investigated in their ability to promote wound healing [13e15].
FN is a large protein that is known to bind GFs from several
families [16e18]. However, for this process to be efﬁcient, the
molecule needs to be unfolded to display GF binding regions [18].
Plasma FN exists as a dimer and consists of three types of modules,
FNI, FNII and FNIII (Fig. 1a). Once secreted by cells, the globular
conformation of the protein changes into a ﬁbrillar one through anPEA. a) Fibronectin molecule with domains depicted; b) ﬁbronectin assembly on two
FN assembly is triggered and networks are assembled; c) scheme of synergistic effect of
of integrin binding site effectively enhances outside-in signalling and allows to VEGFR
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itate FN-FN interaction and assembly of FN networks [19]. Cell
adhesion peptide motifs such as RGD and its synergy sequence
PHSRN in the central cell binding III9-10 domain interact with cells
by binding integrins, whereas the heparin II binding domain in
FNIII12-14 can bind different GFs [16e18]. Spontaneous FN ﬁbrillo-
genesis has been described as FN absorbs onto PEA that re-
capitulates the natural organization of FN in the ECM [20,21] and
results in high availability of integrin and GF binding regions
(Fig. 1b). Since the integrin binding region (FNIII9-10) and the GF
binding region (FNIII12-14) are adjacent to each other, this organi-
zation of FN on PEA promotes crosstalk between integrins and GF
receptors and then synergistic integrin and GF receptor signalling
[22,23]. In this study, FN is assembled into ﬁbrillar nanonetworks
on PEA to engineer synergistic VEGF-presenting microenviron-
ments that promote vasculogenic responses in endothelial cells
(Fig. 1c). This biomimetic system stimulates pro-angiogenic pro-
cesses both in vitro and in vivo using ultra low doses of the GF, and
thus represents a robust and safe strategy to improve vasculariza-
tion in tissue engineering approaches.
2. Material and methods
2.1. Polymer surfaces and scaffolds
Poly(methyl acrylate) (PMA) and poly(ethyl acrylate) (PEA)
sheets were prepared by radical polymerization of methyl acrylate
and ethyl acrylate solutions using 1% benzoin as photoinitiator.
Thin ﬁlms were prepared by spin-coating PMA (6%) and PEA (2.5%)
solutions in toluene on cleaned glass cover slips for 30 s at
3000 rpm and 2000 rpm, respectively. Before use, samples were
oven dried at 60 C and vacuum extracted.
PMA and PEA scaffolds were fabricated using a 3D-printed PVA
template (Ikasia Technologies SL software). The scaffold template
consisted of stacked layers of aligned ﬁbres of 400 mm diameter,
with a ﬁbre-ﬁbre distance of 300 mm. The ﬁbres in a layer were
perpendicularly oriented in respect to the previous one in order to
create a mesh of PVA ﬁbres that was used as a template for thermal
polymerization of methyl or ethyl acrylate monomer. The reaction
was carried out at 60 C for 24 h using 1% benzoyl peroxide as
initiatior and 2% ethylene glycol dimethacrylate as crosslinker. After
the polymerization, the PVA template was dissolved in water and
resulting scaffolds were washed several times in ethanol to remove
all traces of PVA ﬁbres, dried at vacuum, and cut in cylindrical disks
of 5 mm diameter and 2 mm thickness.
2.2. Substrate functionalization with proteins
Spin-coated polymer samples were sterilized under UV for
20 min. Polymers were coated with a human plasma ﬁbronectin
(FN) solution (20 mg/ml, recombinant human VEGF 165, R&D Sys-
tems) for 1 h, washed with PBS, and incubated in VEGF (25 ng/ml,
R&D) for 1 h. Control samples without either FN or VEGF were
incubated in PBS for the same time as coated samples. Function-
alized substrates were washed with PBS prior to further experi-
ments. All incubations were done at room temperature.
To collect plasma FN carrying the D to E mutation in the RGD
motif in FNIII10 module, we generated inducible Mx-Cre mice with
heterozygous FN gene: one allele with ﬂoxed FN [24] and the other
allele with themutation FNRGE [25]. After Cre induction in liver by 3
intraperitoneal injections of 250 mg polyinosinic-polycytidylic acid
at 2-day intervals, blood was collected from FNwt/wt and FNﬂox/
RGE;Mx-Cre mice using 0.5 M EDTA as anticoagulant in non-
heparinized capillaries, centrifuged at 3000 rpm for 20 min and
the plasma FN was puriﬁed from the supernatant (plasma) usinggelatin-Sepharose (GE Healthcare Life Sciences) afﬁnity chroma-
tography adapted to minicolumns (Poly-Prep, Bio-Rad). Brieﬂy, the
columns were washed with 0.5 NaCl in 10 mM Tris-HCl pH 7.4 and
FNwas eluted with 2M urea in TBS (0.15M NaCl in 10 mM Tris-HCl,
pH 7.4) and dialyzed against TBS. Puriﬁed FN was analyzed by 8%
SDS-PAGE and stained with Coomassie brilliant blue, and by
Western blot. Wild-type and mutant FN containing RGE were used
for the coating in the same way as the human puriﬁed FN (20 mg/
ml).
FN was adsorbed overnight onto the scaffold from a protein
solution (20 mg/ml) at 37 C. Then, 1% bovine serum albumin (BSA)
was adsorbed for 30 min at room temperature before exposure to
VEGF in a PBS solution (10 mg/ml) for 1 h. Protein incubation was
facilitated by vacuum allowing the solution to enter into the scaf-
fold pores. Samples were rinsed in PBS to remove non-adsorbed
proteins and kept in PBS until implantation.
2.3. Atomic force microscopy
Functionalized planar substrates were washed three times with
ultrapure water followed by drying with nitrogen. Sample surfaces
were imaged with atomic force microscope NanoWizard 3 (JPK)
using a MPP cantilever (Bruker) with spring constant 3 N/m and
resonance frequency of 75 kHz in tapping mode.
2.4. ELISA
VEGF bound to ﬂat substrates was assayed indirectly by
measuring remaining VEGF in coating solution with sandwich
ELISA kit according to manufacturer's instructions (DuoSetDY293B,
R&D Systems). Levels of phosphorylation of ERK1/2 in human
umbilical vascular endothelial cells (HUVEC) seeded onto func-
tionalized surfaces were assesses after 30 min incubation using
DuoSet ELISA kit following manufacturer's instructions (Duo-
SetDYC1018B, R&D Systems).
2.5. Western blotting
Cells were lysed and processed under denaturing and reducing
conditions. Then, proteins were transferred to PVDF membranes in
a semidry blotter. After the transfer, membranes were blocked with
5% BSA in Tris-buffered saline with 0.1% Tween 20 (TBST) for one
hour at RT, and then cut at the 70 kDa mark to allow probing for
pPLCg1/pFAK and a-tubulin simultaneously.
For phospho-PLCg1, blots were incubated overnight at 4 C with
rabbit polyclonal anti phospho-PLCg1 antibody (Tyr 783) (Cell
Signalling) diluted 1:1000 in 2% BSA-TBST. At the same time, a-
tubulin was probed with mouse monoclonal anti a-tubulin anti-
body (Santa Cruz Biotechnology) diluted 1:500 in 2% BSA-TBST,
overnight at 4 C. The day after, blots were washed three times
for 5 min in TBST at RT. The phospho-PLCg1 blot was probed with
HRP-linked donkey monoclonal anti-rabbit antibody (GE Health-
care) diluted 1:10000 in 2% BSA-TBST and the a-tubulin blot with
HRP-linked donkey monoclonal anti-mouse antibody (GE Health-
care) diluted 1:10000 in 2% BSA-TBST for one hour at RT, washed six
times for 5 min in TBST and developed using ECL Prime chem-
iluminiscent kit (GE Healthcare). For phospho-FAK, blots were
probed using a polyclonal rabbit anti p-FAK (Tyr 397) (Merck Mil-
lipore) diluted 1:500 in 2% BSA-TBST, using a HRP-linked donkey
monoclonal anti-rabbit antibody (GE Healthcare) diluted 1:10000
in 2% BSA-TBST as secondary for chemiluminiscent detection and
the same protocol for a-tubulin described above. Blots were then
washed six times for 5 min with TBST and bands developed using
ECL Prime (GE Healthcare). All blots were imaged with a Syngene
PXi 5 gel documentation system (Syngene, UK) and analyzed using
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2.6. Heparin II domain availability
After coating with FN, a monoclonal antibody for the FNIII12-14
domain (also known as Heparin II domain) was used (Santa Cruz
Biotechnologies, sc-18827) in dilution 1:30 at 37 C for 2 h. Samples
were washed three times with PBS/0.5% Tween 20. An anti-mouse
IgG horse radish peroxidase (HRP)-conjugated antibody (Invi-
trogen, 626520) was then used in dilution 1:2000 at room tem-
perature for 1 h. After washing twice, samples were exposed to the
substrate solution (R&D, DY999) for 20 min at room temperature in
the dark. A stop solution (R&D, DY994) was added before reading
the absorbance at 450 nm.
2.7. VEGF-speciﬁc immunogold reaction
Planar samples coated with FN and with and without VEGF
coating were ﬁxed with 4% formaldehyde, incubated with primary
antibody against human VEGF (Santa Cruz Biotechnologies, sc-
57496) diluted 1:50 in PBS for 1 h, and after three washes with
0.5% Tween 20 in PBS, goat anti-mouse secondary antibody labeled
with 15 nm gold nanoparticles (Aurion 815.022) was added in
dilution 1:20 in PBS and left to react for 1 h. After immunoreaction,
excess secondary Ab was removed by two PBS washes; samples
were ﬁxed with 4% formaldehyde, washed three times with ultra-
pure water, then gently dried with nitrogen and imaged with AFM.
2.8. Scanning electron microscopy
Scaffold structure was characterized by scanning electron mi-
croscope (JEOL JSM-6300) using gold-sputtered samples. The
working distance was ﬁxed at 15 mm and acceleration voltage at
13 kV. SEM images were obtained in both longitudinal and trans-
versal sections.
2.9. Cell cultures
HUVEC (Cellworks) were maintained in HLVEC complete me-
dium (Cellworks). Cells with less than 10 population doublings
were used for all experiments. For network formation assays, cells
were seeded at 10,000 cells/cm2. Seeding was done on protein-
functionalized and control polymer substrates, and cells were left
to adhere in CO2 incubator at 37 C. After 16 h, medium was
removed and replaced with a ﬁbrinogen solution (20 mg/ml) in
HLVEC basal media, containing also 50 U/ml of thrombin and
1.2 mg/ml of aprotinin. To allow complete ﬁbrinogen clotting,
samples were placed in CO2 incubator for 1 h. After clotting, ﬁbrin
matrix was covered with 0.5 ml HLVEC complete media with 25 ng/
ml of VEGF where required, and samples were kept at 37 C for 6
day period, with media changed every second day. For phosphor-
ylation experiments, cells were seeded at density 15,000 cells/cm2
on protein-functionalized and control polymer substrates, and
incubated in CO2 incubator at 37 C. After 30 and 180 min,
respectively, cells were washed with PBS, and then incubated with
lysis buffer for 15 min on ice. Cell lysates were harvested and stored
at 80 C until assayed. For colocalization experiment, cells were
seeded on control and protein-functionalized substrates at the
density 6000 cells/cm2, and incubated in growth medium for 24 h.
2.10. Murine fat pad vascularization model
All animal experiments were performed in accordance with the
Georgia Institute of Technology's Animal Care and Use Committee.
Male mice (8 weeks old C57BL/6J mice, Jackson Laboratory) wereanesthetised with isoﬂurane and one dose of sustained-release
buprenorphine (1 mg/kg, IP) was given to provide 72 continuous
hours of pain relief. The hair on the abdomen areawas removed and
skin disinfected with alcohol and chlorhexidine. A 10 mm midline
incision was performed at the mid abdomen. The epididymal fat
pad (EFP) was gently exposed and spread. One scaffold was
implanted per EFP site, right and left. PMA or PEA scaffolds, func-
tionalized with FN and VEGF, were placed on the centre on the EFP,
thenwrapped using the EFP tissue and sealed using a poly(ethylene
glycol) sealant. The abdominal incision was closed by using a
simple interrupted suture pattern with degradable suture, while
the skin layer was closed with wound clips. At the endpoint of the
study, 14 days post-transplant, mice were anesthetized with iso-
ﬂurane, and 200 ml of DyLight 488 labeled Lycopersicon Esculentum
(tomato) lectin (Vector Laboratories) in sterile saline was injected
into the jugular veinwith an insulin syringe. The lectinwas allowed
to circulate for 5 min under anaesthesia. Perfusion was performed
at room temperature. After the lectin was bound to the endothe-
lium, the abdominal cavity was opened with a midline incision and
the original implant site. The vena cava was severed and the cir-
culation ﬂushed with saline to eliminate blood and excess lectin
from the circulation, necessary for imaging purposes. All grafts
were explanted, formalin ﬁxed, parafﬁn embedded, and sectioned
using a microtome.
2.11. Fluorescence staining and imaging
Cells from in vitro assays were washed with PBS, and then were
ﬁxed with 4% formaldehyde and permeabilized with 0.1% Triton X-
100 in PBS. For network formation assay, cytoskeleton was labeled
with BODIPY-FL Phallacidine (Life Technologies) diluted 1:100 in
PBS, and nuclei were stained with Hoechst 33342 (NucBlue, Life
Technologies) using 1 drop per 0.5 ml PBS. Images were taken with
ﬂuorescence microscope Zeiss Observer Z1 using green and blue
ﬁlters; 5 areas were imaged per each sample. For phosphorylated
VEGF receptor (VEGFR-2) staining, rabbit monoclonal antibody
(Cell Signalling, VEGFR-2 Tyr1175) was used in 1:100 dilution and
was visualized with rhodamine donkey anti-rabbit IgG (Santa Cruz
Biotechnologies, sc-2095). For integrin e VEGFR-2 colocalization
study, integrin av/CD51 goat polyclonal antibody (R&D Systems),
and VEGFR-2 rabbit monoclonal antibody (Cell Signalling) were
used in combination with Alexa Fluor 546 donkey anti-goat and
Alexa Fluor 647 chicken anti-rabbit secondary antibodies (Life
Technologies); samples were mounted with Vectashield with DAPI
(Vector Labs) and imaged using blue, red and far red ﬁlter.
Parafﬁn sections from in vivo experiment were ﬁrst imaged
using green ﬁlter to analyze intact ﬂuorescence from vascular
structures in the scaffolds pores; then sections were deparafﬁnized,
stained for actin with Rhodamine Phalloidin (Life Technologies),
mounted with Vectashield with DAPI to stain the nuclei, and ﬁnally
imaged using red, green and blue ﬁlter as well as bright ﬁeld.
2.12. Data analysis
Image analysis for HUVEC alignment was done in ImageJ using
object counting, and area and length measurement algorithms
(details in Suppl. Fig. S1). Ten areas were analyzed for each sample,
and means and standard deviations were calculated. For quantiﬁ-
cation of lectin ﬂuorescence in individual pores in scaffold sections
selected areas of interest were calculated in ImageJ; in total, 30
pores were analyzed per condition. For ELISA, samples were
assayed in triplicates, and means and standard deviations were
calculated. For statistical analysis, either one-way ANOVA with
Tukey post-test or unpaired two-tailed t-test was performed where
applicable using GraphPad Prism5 software.
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3.1. VEGF binding
We quantiﬁed the total amount of VEGF bound to PEAþFN and
PMAþFN surfaces as well as the availability of GF-binding domain
(FNIII12-14) using ELISA (Fig. 2a and b). Although the surface density
of VEGF on FN nanonetworks on PEA was slightly elevated in
comparison to VEGF amount on FN-coated PMA, the difference was
not signiﬁcant (Fig. 2a). On the other hand, we observed signiﬁ-
cantly higher availability of GF binding domain for FN (FNIII12-14) on
PEA in comparison to PMA (Fig. 2b), which should favor speciﬁc
VEGF binding on ﬁbrillar FN on PEA compared to globular FN on
PMA. (Please note that we'll use the term globular FN for molecules
on PMA even if the process of adsorption might lead to partial
unfolding as reﬂected in AFM images shown in Fig. 2e).
We conﬁrmed that VEGF was speciﬁcally bound to PEAþFN
using AFM. Firstly, we hypothesized that considering the size of
VEGF and that FN on PEA is organized into nanonetworks [21],
VEGF-FN structures on PEAþFN would be detectable by scanning
the surface with AFM. The presence of VEGF on FN ﬁbers was
difﬁcult to observe by AFM when VEGF was adsorbed on PEAþFN
compared to the control (FN-coated PEA without VEGF, Fig. 2c).
Therefore, to conﬁrm VEGF binding and speciﬁcity on FN ﬁbrils, weFig. 2. Characterization of VEGF binding to FN-coated PEA and PMA: a) VEGF bound to FN-c
of FN was higher on PEA than on PMA c) AFM images of FN-coated PEA incubated with and
Blue arrows depict approximate position of FNIII12-14 domains (GF binding site) with no GF
VEGF molecules. d) Scheme of immunogold binding to VEGF immobilized on surface. An exp
VEGF and IgG representation, respectively; structures were processed in PyMol (scheme not
in presence of the GF (left) and without (right). White peaks represent VEGF bound to PEA
molecules (PMA) are visible on VEGF negative controls (right). Unpaired two-tailed t-test
pretation of the references to colour in this ﬁgure legend, the reader is referred to the webused an antibody against VEGF and then a secondary antibody
labeledwith a 15 nm gold nanoparticle which is easily visualized by
AFM. We expected an approximate height of the protein-
nanoparticle complex bound to the FN-coated surface to be
~30 nm (Fig. 2d). Fig. 2e shows that after VEGF coating, structures of
the expected height were present only on FN-coated PEA samples,
while FN-coated PMA samples did not show any structures apart
from globular FN. No nanogold could be observed on PEA and PMA
controls without VEGF coating. This result conﬁrms that VEGF
binds to FN nanonetworks organized on PEA and that VEGF binding
to FN does not occur when FN adsorbed in a globular-like confor-
mation, such as the FN-coated PMA control. Together, Fig. 2 in-
dicates that VEGF binds speciﬁcally to FN assembled on PEA. Fig. 2e
shows immunogold images, with samples under extensivewashing
during the incubation of antibodies that results in removal of all
nanogold particles with lack of speciﬁc interactions between anti-
bodies and VEGF. In contrast to this, Fig. 2a shows quantiﬁcation of
VEGF after adsorption and standard washing on the polymers, as it
was done before cell culture.
3.2. HUVEC organization
We evaluated the ability of VEGF bound on FN nanonetworks,
(i.e. VEGF as a coating: PEAþFNþVEGFc) to induce the organizationoated PEA and PMA substrates assessed by ELISA. b) Availability of GF binding domains
without VEGF - images show stretched FN molecules (with monomer length ~ 50 nm).
present, green arrows show thickening of FNIII12-14 domains, suggesting presence of
ected structure height was estimated based on PDB structures 2VPF and 1IGY used for
to scale). e) AFM imaging of FN-coated substrates after immunogold reaction with VEGF
whereas no VEGF was detected on PMA (left). Only FN network (PEA) or scattered FN
was performed for statistical analysis; ***P < 0.001; ns ¼ non-signiﬁcant. (For inter-
version of this article.)
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exposed to globular FN on PMA (PMAþFNþVEGFc) as well as FN
nanonetworks on PEA with soluble VEGF in the culture medium
(PEAþFNþVEGFm, using higher concentration of VEGF e positive
control). HUVEC were seeded onto material surfaces. After cell
attachment, cultures were covered with a ﬁbrin matrix, and ﬁnally
the whole construct was immersed in growth media (Fig. 3a). In
this system, cells adhered ventrally to the FNþVEGF functionalized
polymer surface whereas the dorsal top layer provided a support-
ing 3D environment representing a simpliﬁed extracellular matrix
into which cell networks could form.
After 6 days of incubation, cells seeded on PEAþFNþVEGFc
showed clear network alignment on the level of the polymer sur-
face, whereas cells on PMAþFNþVEGFc exhibited considerably less
developed cellular networks (Fig. 3b). For the positive control, it is
noteworthy that fresh VEGF was included each time the medium
was changed (Fig. 3b, FNþVEGFm) e the total amount of soluble
VEGF used was ~6 times higher than VEGF adsorbed on the sur-
faces. Notwithstanding this large difference in the amount of VEGF
used, cell sprouting into the overlying ﬁbrin matrix was observed
for cells growing on PEAþFNþVEGFc (coating) (Fig. 3c).
Quantiﬁcation through image analysis of these cellular net-
works at the material interface revealed signiﬁcant differences
among groups (Fig. 4). The total cell number was similar between
PEA and PMA, the samewith both no VEGF and VEGF on the coating
(i.e., PEAþFN, PEAþFNþVEGFc, PMAþFN and PMAþFNþVEGFc) but
was increased for VEGF in the culture medium (e.g.
PEAþFNþVEGFm and PMAþFNþVEGFm) (Fig. 4a, blue). However,
cell attachment and spreading was better developed on PEAþFN
surfaces (þ/ VEGFc) when compared to PMAþFN surfaces (þ/
VEGFc) as shown by the total area coverage; also PMAþFNþVEGFmFig. 3. HUVEC forming network structures on functionalized substrates: a) Scheme of system
top and ﬁnally covered with a thin layer of ﬁbrin matrix. b) Fluorescence images of cell cult
comparison to PMA (central images), negative controls (samples with no GF coating) and po
are also shown (left and right, resp.); scale bar represents 200 mm c) Stack images showing 3D
the level of synthetic polymer substrate, height difference between bottom and top imagehad much weaker effect on coverage in comparison to
PEAþFNþVEGFm (Fig. 4a green). This was also supported by larger
single cell area on PEAþFN surfaces (þ/ VEGFc) compared to
PMAþFN surfaces (þ/ VEGFc) (Fig. 4a, grey). Interestingly, the cell
size showed decreasing trend on PEA when going from FN across
FNþVEGFc to FNþVEGFm, with PEAþFNþVEGFm being not
signiﬁcantly different from all PMA samples (Fig. 4a, grey). This can
be indicative of cell reorganization towards networks triggered by
VEGF and then less space is needed per a single cell.
Cell alignment was quantiﬁed by measuring total length of
aligned structures, average length of these structures and the
number of junctions per image (Fig. 4b). All these parameters were
higher for cells on PEA surfaces with VEGF (PEAþFNþVEGFc and
PEAþFNþVEGFm) than on corresponding PMA surfaces (Fig. 4b).
For both PEA and PMA a stepwise increase was observed from
polymerþFN to polymerþFNþVEGFc to polymerþFNþVEGFm
(Fig. 4b). Note that the number of cells on both PEA and PMA sur-
faces was similar (Fig. 4a). However the total length of aligned
structures formed on PEA was higher compared to PMA (poly-
merþFNþVEGFc) as the total length of structures is dictated by the
alignment of the cells for the same number of cells.
For conditions with VEGFm, the three parameters in Fig. 4bwere
still higher on PEA than PMA whereas it is notable that there were
no statistical differences in total length and number of junctions
between PEAþFN and PMAþFN in the absence of VEGF. This sug-
gests that VEGF in the media might be adsorbed on the FN coated
polymers as well as being free in the media and thus VEGF would
promote cell organization more effectively being presented from
PEAþFN as well as in the media. Overall, this quantitative analysis
indicates that VEGF bound to FN nanonetworks on PEA has a pos-
itive effect in HUVECs reorganization into aligned structures.components: After polymers were coated with FN and VEGF, cells were seeded on the
ures after 6 days: FNþVEGFc coated PEA showed higher degree of aligned structures in
sitive controls (samples with no GF coating but with VEGF constantly present in media)
sprouting of HUVEC cells into the ﬁbrin matrix on PEAþFNþVEGFc: bottom image is at
is 200 mm; scale bar represents 100 mm.
Fig. 4. Image analysis of HUVEC behavior on functionalized substrates: a) A merged image of DAPI staining and a mask from actin staining; these raw images were used for
quantiﬁcation of cell count and cell spreading after 6 days of culture. The cell number (blue bars) did not vary apart from FNþVEGFm controls (FN-coated polymer substrates with
VEGF present in medium). The total area coverage (green bars) was higher on PEA when compared to PMA for individual conditions: FN coated only (FN), FN and VEGF coated
(FNþVEGFc), and FN-coated with VEGF in medium (FNþVEGFm), revealing better spreading on PEA-FN surfaces. This is supported by larger single cell area (grey bars) on PEA
samples when comparing PEAþFN vs. PMAþFN and also PEAþFNþVEGFc vs. PMAþFNþVEGFc. b) Simpliﬁed binary image of actin staining used for quantiﬁcation of cell orga-
nization; statistical analysis of total length of aligned structures per image (orange bars) as well as an average length of these structures (red bars) including number of junctions per
image (cream bars) showed higher level of cell alignment on PEAþFNþVEGF samples when compared to their respective PMAþFNþVEGF controls. Total length and number of
junctions were signiﬁcantly higher in PEAþFNþVEGFc samples when compared to PEAþFN control, which clearly proved vasculogenic effect of VEGF coating. One way ANOVAwith
Tukey's multiple comparison post-test was done for statistical analysis; *P < 0.05; **P < 0.01; ***P < 0.001; ns ¼ non-signiﬁcant. (For interpretation of the references to colour in this
ﬁgure legend, the reader is referred to the web version of this article.)
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Fig. 5. Effect of ﬁbronectin RGD/ RGE mutation on HUVEC behavior on PEA. a) Representative ﬂuorescence images of HUVECs cultures after 6 days of incubation showed lower
cell attachment and spreading on mFN-RGE coated surfaces when compared to mFN-WT (RGD). Scale bar represents 200 mm b) Image analysis of parameters characterizing cell
attachment and formation of aligned structures revealed that the mutated mFN-RGE signiﬁcantly decreased HUVEC numbers and spreading on PEA surfaces when compared to
mFN-WT; this was valid also in presence of VEGF for both VEGF in coating (VEGFc) and VEGF in media (VEGFm) (blue, green and grey bar graphs). mFN-RGE also impaired the
network formation in comparison to mFN-WT, in VEGFm samples (yellow, red and cream bar graphs), and partially in VEGFc samples (red bar graph). For statistical evaluation, one
way ANOVA with Tukey's multiple comparison post-test was performed; *P < 0.05; **P < 0.01; ***P < 0.001; ns ¼ non-signiﬁcant. (For interpretation of the references to colour in
this ﬁgure legend, the reader is referred to the web version of this article.)
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Fig. 6. Integrin av and VEGF receptor colocalization in HUVEC on polymerþFNþVEGFc surfaces after 24 h of incubation: a) Cells on PEA coated with FN and VEGF (PEAþFNþVEGFc)
stained in red for integrin av and in green for VEGFR-2; top images represent individual channels while the bottom image shows their merge; white rectangles point out example
area where both proteins were detected in the same location which resulted in yellow colour in the merge image. Detailed view of this area for integrin av, VEGF receptor and their
merge is shown on b), c) and d), respectively; e) Cells on PMA coated with FN and VEGF (PMAþFNþVEGFc) stained in the same way as on the PEA sample with individual red and
green channels at the top and merge image at the bottom; integrin av staining is present while clear VEGFR-2 staining is not obvious (the faint staining is mainly associated with
background). Scale bar represents 20 mm on every image. (For interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
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The RGD motif in the FNIII10 domain is involved in integrin
binding to FN. A mutant FN containing RGE (mFN-RGE) that
signiﬁcantly impairs cell adhesion [26] was engineered and used
here to examine the role of integrin binding in the process of
HUVEC organization on FN nanonetworks on PEA. We ﬁrst
conﬁrmed that mFN-RGE is organized into nanonetworks on PEA,
which suggests that, as expected, the RGD sequence itself is not
involved in the process of PEA-driven FN assembly (Suppl. Fig. S2)
[21]. Wild-type plasma FN from mouse (mFN-WT) showed com-
parable results to human FN in HUVEC organization experiments
(Suppl. Fig. S3). In experiments where HUVEC responses were
monitored on PEAþmFN-WT and PEAþmFN-RGE (Fig. 5a), cell
attachment was signiﬁcantly affected as parameters such as cell
size, cell number and area coverage were all considerably lower in
all conditions using PEAþmFN-RGE in comparison to PEAþmFN-
WT (Fig. 5b e blue, green and grey).
Parameters characterizing formation of cellular networks (total
length of aligned structures, their average length and number of
junctions) were signiﬁcantly lower on PEAþmFN-RGE with VEGFm
compared to PEAþmFN-WTwith VEGFm (Fig. 5b e orange, red and
cream). Also for PEAþFNþVEGFc-functionalized surfaces, the
average length of cellular structures was signiﬁcantly lower on
PEAþmFN-RGE in comparison to PEAþmFN-WT (Fig. 5b e red,
compare VEGFc). Interestingly, on VEGF coated surfaces the effect
of the mutation was not as obvious because the total length and
number of junctions were not signiﬁcantly different between
PEAþmFN-RGE and PEAþmFN-WT (Fig. 5b e orange and cream,
compare VEGFc). It is clear that the aligned structures on
PEAþmFN-RGE with VEGF coating were shorter when compared
with PEAþmFN-WT. However, cells on PEAþmFN-RGE were still
able to form network structures of comparable total length and
with similar number of junctions.3.4. Cell signalling
To test whether PEA-driven integrin/VEGF presentation drives
HUVEC organization through a synergistic mechanism, we per-
formed co-localisation and signalling experiments. VEGF was
adsorbed onto FN-coated PEA and PMA surfaces and then we
examined colocalization of integrins and VEGFR-2 at the individual
cell level using immunoﬂuorescence (Fig. 6). We observe colocali-
zation of av and VEGFR-2 (but not of b1 results not shown) on
PEAþFNþVEGFc (Fig. 6aed). There is no colocalization of receptors
on PMA (Fig. 6e) which supports the idea that VEGF bound next to
the RGD sequence facilitates simultaneous VEGFR-2 and integrin av
binding within the same nanoscale cluster.
We assessed VEGF receptor (VEGFR-2) phosphorylation as a
direct measure of VEGF signal activation. Immunoﬂuorescence for
phosphorylated VEGFR-2 was performed on HUVEC cultured on
tissue culture plastic, after cells were stimulated with 25 ng/ml of
VEGF for two different time periods (2 and 30 min). After 2 min of
stimulation, the phosphorylated receptor was observed while after
30min incubation no phosphorylationwas detected (Suppl. Fig. S4)
[27]. This result showed that the time window for VEGFR-2 phos-
phorylation is very narrow and so detection of VEGFR-2 phos-
phorylation in response to the surfaces challenging considering
that cells require some time to adhere. To investigate signalling, we
examined phosphorylation of phospholipase C gamma 1 (pPLCg1)
as a downstream effector which is activated by VEGFR-2 [4],
phosphorylation of focal adhesion kinease (pFAK) that is activated
after integrin binding and clustering [28], and phosphorylation of
ERK1/2 (pERK1/2) a downstream effector which is activated via the
mitogen activated protein kinase (MAPK) branch of GF receptor and
integrin signalling [4].
No differences were observed in pFAK when no VEGF or VEGF
was used as a coating on both PEA and PMA. pFAK was signiﬁcantly
higher on PEA when VEGF was added in the medium, which sug-
gests that soluble VEGF reinforces adhesion to FN nanoﬁbrils but do
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signiﬁcantly higher phosphorylation of PLCg1 and ERK1/2 was
observed on PEAþFNþVEGFc compared to the other conditions (no
VEGF and VEGF in the medium for both PEA and PMA, Fig. 7aec).
We note that higher ERK1/2 phosphorylation on PEAþFN and
PEAþFNþVEGFc compared to the corresponding PMA surfaces was
not translated into a higher level of cell proliferation (similar
number of cells show on Fig. 4a) but must have played role in the
ability of cells to migrate and organize on the surfaces [29].
Importantly, differences were found between PEA based sam-
ples themselves for VEGF related signalling. FN nanonetworks on
PEA coated with VEGF (PEAþFNþVEGFc in Fig. 7) showed a higher
level of both PLCg1 and ERK1/2 phosphorylation in comparison
with PEAþFN with no VEGF and PEAþFNþVEGFm (Fig. 7aec).Fig. 7. ERK1/2, PLCg1 and FAK phosphorylation in HUVEC on PEA and PMA coated with ﬁbro
higher phosphorylation in cells on PEA (green bars) than on PMA (orange bars). On PEAþF
ylation when compared to PEAþFN without VEGF (FN). PEAþFN sample with VEGF present
PEAþFN with VEGF in media only (VEGFm) did not vary from PEAþFN control. b) Represen
FAK proteins in HUVEC lysates after 30 min and 2 h incubation, respectively; bands were nor
PLCg1 and phospho-FAK western blot bands. Enhanced VEGF signalling is observed on PEAþ
ERK1/2 stimulation depicting the role of PLCg1 and FAK as early effectors of VEGFR-2 and in
leads to activation of the c-Fos transcription factor. Its formation of heterodimers with c-Jun
pERK1/2 can lead to enhanced ERK1/2 stimulation. For statistical evaluation, one way ANO
***P < 0.001; ns ¼ non-signiﬁcant. (For interpretation of the references to colour in this ﬁgInterestingly, ERK1/2 phosphorylation on PEAþFN shows no dif-
ference for VEGFc and VEGF that has been both coated and added to
the media (PEAþFNþVEGFc and PEAþFNþVEGFcm in Fig. 7a), i.e.
there is no additional ERK1/2 phosphorylation related to the
presence of VEGF in the medium when the GF is already on the
coating. It is further noteworthy that the lack of effect of VEGF in
the medium on pERK1/2 is supported by similar levels on
PEAþFNþVEGFm over PEAþFN (Fig. 6a).
In summary, these results conﬁrm enhanced effects of FN bound
ligands, as only the bound VEGF in close vicinity to integrin binding
sites was able to stimulate cells at the highest levele i.e. PEAwhere
VEGF was bound on FN nanonetworks in synergy with integrins.
Soluble VEGF in the medium did not have any signiﬁcant effect at
this early time point.nectin: a) ELISA quantiﬁcation of pERK1/2 after 30 min incubation showed signiﬁcantly
N substrates, VEGF-coated sample (VEGFc) showed higher level of ERK1/2 phosphor-
in both coating and media (VEGFcm) showed no difference from PEAþFNþVEGFc, and
tative images of western blot membranes with detected phospho-PLCg1 and phospho-
malized against a-tubulin; c) Quantiﬁcation of phosphorylated proteins from phospho-
FNþVEGFc d) Scheme of individual VEGFR-2 and integrin signalling pathways towards
tegrin signal transduction; phosphorylated mitogen-activated kinase 1 and 2 (ERK1/2)
and binding to DNA. e) Scheme of synergistic VEGFR-2 and integrin signalling towards
VA with Tukey's multiple comparison post-test was performed; *P < 0.05; **P < 0.01;
ure legend, the reader is referred to the web version of this article.)
Fig. 8. Murine fat pad model for vascularization showed better response for PEA than for PMA scaffolds; a) Fabrication of scaffolds: PEA and PMA was polymerized in 3D printed
PVA templates to form scaffold with interconnected channels. b) Quantiﬁcation of lectin ﬂuorescence representing endothelial cells inﬁltrating PEAþFNþVEGFc and
PMAþFNþVEGFc (**P < 0.01). c) Representative images of thin sections of explanted PEA and PMA scaffolds show endothelial cell speciﬁc lectin ﬂuorescence staining of original fat
pad tissue as well as new endothelial cells inside the pores; ﬂuorescence inside the pores was used for quantiﬁcation. Limits between scaffolds and fat pad tissue are shown by the
yellow dashed line; pores within the scaffold are delimited by blue dashed lines. Fat pad tissue surrounds completely both PMA and PEA scaffods. d) Detailed image of newly formed
tissue inside a pore of the PEAþFNþVEGF scaffold showing vascular network; lower magniﬁcation image on the right shows position of the pore in the scaffold and link to the
original fat pad tissue through a channel. e) Lack of formation of tissue inside pores of the PMAþFNþVEGF scaffolds together with the corresponding bright ﬁeld image that has
allowed univocal identiﬁcation of pores. The corresponding bright ﬁeld image for PEA is include in Supplementary Fig S5e. Cytoskeleton is in red, nuclei in cyan, scale bars represent
100 mm. (For interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
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3.5. In vivo vascularization
To test whether our system can stimulate vascularization in vivo,
we fabricated PEA and PMA scaffolds using a 3D printed template
(Fig. 8a, Suppl. Fig. S5a, S5b). Experiments with murine mesen-
chymal stem cells (MSCs) demonstrated robust cell adhesion and
scaffold inﬁltration (Suppl. Fig. S5c). For in vivo studies, PEA and
PMA scaffolds were coated with FN and VEGF, and implanted in
murine epididymal fat pads. After two weeks, mice were perfused
with a solution of ﬂuorescent lectinwhich binds to endothelial cells
in functional vasculature. After ﬁxing and sectioning, lectin ﬂuo-
rescence was quantiﬁed inside the scaffold pores. Signiﬁcantly
higher ﬂuorescence was detected inside the pores for
PEAþFNþVEGFc scaffolds in comparison to PMAþFNþVEGFc scaf-
folds used as a control (Fig. 8b), showing PEAþFNþVEGFc pro-
moted enhanced levels of vascularization.
Sections were also stained for cytoskeleton and nuclei, and both
for PEAþFNþVEGFc and PMAþFNþVEGFc, a thin layer of the
original fat pad tissue was detected around the scaffold. Also, cell
ingrowth was present in open pores or in pores directly connected
with the original tissue through channels in both PEAþFNþVEGFc
and PMAþFNþVEGFc implants. However, PEAþFNþVEGFc scaf-
folds resulted in higher level of vascularization with newly formed
vessels clearly visible (Fig. 8e, Suppl. Fig. S5e).
4. Discussion
Blood supply is essential for successful tissue engineering stra-
tegies with poor supply leading to ischemic conditions such as in
diabetic wounds and ulcers [30]. The only GF-based product
approved for the treatment of complex wound healing (Regranex©)
contains platelet-derived growth factor-BB (PDGF-BB) and has
limited efﬁcacy along with safety concerns (risk of cancer warned
by FDA in 2008). These concerns result from spatiotemporally un-
controlled and supraphysiological dosing (100 mg/g) to compensate
for clearance from the damaged area.
Clinical trials with VEGF delivery for cardiac repair have not
been successful either, failing to demonstrate signiﬁcant improve-
ment in patients when compared to placebo [31]. As well as for
cardiac application [32], therapeutic VEGF delivery has been stud-
ied for wound healing (reviewed in Ref. [33]) or bone repair
(reviewed in Ref. [34]). However, overall VEGF use in pro-
angiogenic therapies has not been effective thus far [35,36].
Again, use of high GF dose severely limits translation of VEGF use
into clinical practice.
Therefore, there is much interest in the development of pro-
angiogenic biomaterials that present rather than deliver GFs so
that low doses can be used locally without systemic collateral
damage [8,37]. A number of design criteria have emerged over the
years, which combine the use of microenvironments that recapit-
ulate the physiological ECM, in particular the presence of deﬁned
cell adhesion sites [38] and the ability to bind angiogenic factors
and stimulate GF receptors [12,27,38].
A particularly efﬁcient approach has been developed using FN
domains containing both cell attachment and GF binding motifs
(FNIII9-10/FNIII12-14) into ﬁbrin matrices to promote synergistic
integrin/GF receptor signalling [27]. However, this approach relies
on recombinant FN fragments and soft materials.
We have used a material system (PEA) that promotes the self-
organization of FN to present cell adhesion- and GF-binding do-
mains that sequester GFs including VEGF [18,22]. FN nanonetworks
on PEA promoted cell adhesion and maintenance of stem cell
phenotypes in the absence of GFs [20,39e41]. PEA driven FN
nanonetworks allow efﬁcient GF presentation and we have shown
that PEAþFNþBMP-2 increased osteogenic differentiation in MSCscompared with soluble BMP-2 along with bone regeneration in a
critical size defect, [22].
Here, we used PEA to assemble FN molecules and bind VEGF
seeking to promote simultaneous VEGFR-2 and integrin signalling
(Fig. 7e). We found VEGF interactions with FN molecules exclu-
sively on PEA but not on PMA (where FN remains globular) (Fig. 2),
and that in both in vitro (Fig. 3) and in vivo (Fig. 8) tests the vas-
culogenic response was signiﬁcantly enhanced on VEGF-FN-coated
PEA due to efﬁcient VEGF binding to FN, which has been reported to
occur on FNIII12-14 in close vicinity of FN integrin binding domains
[18]. This was achieved with an ultra low dose of GF (as a single
dose) (~5 ng/cm2), which represents a signiﬁcant advantage of this
system over other strategies used so far [13,42,43].
While VEGF has been incorporated into material systems as it
regulates cell migration and proliferation of existing ECs [4] as well
as recruitment of EC-progenitors and perivascular cells to promote
tissue repair [44,45], VEGF crosstalk with integrins still has been
poorly addressed in the design of material systems. We show
colocalization of integrin (av) and VEGFR-2 (Fig. 6). It was previ-
ously shown that phosphorylation of VEGF receptor-2 (VEGFR-2)
was prolonged in association with integrins [46], and ERK1/2
(crucial for gene expression and DNA synthesis) was phosphory-
lated as a result of activation of both integrins and VEGFR-2 via the
FAK/Ras/Raf (integrin based ERK cascade) and PLCg/Raf (VEGFR-2
based ERK cascade) pathways respectively [47,48]. We show
enhanced PLCg phosphorylation when VEGF is presented on
PEAþFN, which reveals enhanced GF signalling in crosstalk with
integrins (Fig. 7).
As the RGD sequence of FNIII10 binds particularly integrins a5b1
and avb3 dimers [16], we hypothesize that these integrins coop-
erate with VEGFR-2 in our system (PEAþFNþVEGFc). The role of b1
was supported by previous results using VEGF in collagen, where
integrin b1 recruitment and VEGFR-2 clustering was linked to
increased DNA synthesis and cell migration [46]. A study using
recombinant fragments of FN (FNIII9-10/FNIII12-14) in ﬁbrin matrices
demonstrated the central importance of a5b1 integrin for improved
EC migration, proliferation and tube-like structure formation while
avb3 was less critical [27]. Our studies show a preference for av to
colocalise with VEGFR-2 on ﬁbrillar FN on PEA (Fig. 6). The role of
integrins in VEGFR-2 mediated crosstalk remains complex and re-
quires further elucidation. For example, avb3 has been related to
VEGF-stimulated initiation of angiogenic programing [49,50], ECs
on FN showed weaker response in comparison to vitronectin,
which binds exclusively avb3, and avb3 (but not b1) was identiﬁed
using a synthetic FNIII10-VEGF fused protein [14].
With respect to use of RGE to determine the role of RGD-
mediated integrin binding, it has been reported that i) FN RGE
mutations impair a5 binding but still allow av binding, and ii) that
engineered FN-RGE mice have the same phenotype as a5 integrin-
null mice [26]. In our study, mFN-RGE showed signiﬁcantly lower
support of HUVEC networks than mFN-WT (RGD) on PEA (Fig. 5),
indicating a key role of integrins a5 and av in this process. However,
at the same time, there were still a small number of cellular
network structures observed in ECs on mFN-RGE (Fig. 5), which
suggests that av could still bind and be involved in synergistic
signalling up to a certain level. This is supported by co-localisation
experiments shown in Fig. 6. Overall, our experiments with mutant
FN containing RGE (mFN-RGE) suggest that both a5 and av integrins
cooperate in HUVEC stimulation (together with VEGF) (Fig. 5).
Increased vascularization in vivo showed that PEA promoted
presentation of VEGF is functional and that in vitro effects can be
translated in vivo. A major advantage of our system is that the VEGF
presentation occurs from a ‘solid-phase’ allowing enhancement
through synergy with adhesion signalling [51]. The solid phase use
of VEGF involves presentation rather than delivery and the synergy
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target effects should be avoided. We used a solution of VEGF at a
concentration 10 mg/ml to saturate all the binding sites of FN on the
surface of PEA. Since the amount of FN adsorbed on these polymers
is ~400 ng/cm2 (from a solution of 20 mg/ml) [21], the maximum
amount of VEGF that remains speciﬁcally bound on the surface
is < 50 ng/cm2. Considering the geometry of the scaffold (a mesh of
channels with diameter 400 mm separated at a distance of 300 mm),
the surface to volume ratio of the pores is 100 cm1, which allows to
calculate the equivalent concentration of VEGF within the scaffold
volume to be < 5 mg/ml. Note that this concentration is at least 50%
lower than the standard amount of VEGF used in vascularization
studies using advanced material systems [52e54].
5. Conclusions
We have engineered a system that promotes vascularization
in vitro and in vivo using low doses of VEGF bound to a material
surface. The system is based on a polymer (PEA) that organizes FN
into nanonetworks to expose simultaneously the integrin (FNIII9-
10) and GF (FNIII12-14) binding regions of FN to promote speciﬁc
VEGF binding and then synergistic integrin/VEGF receptor signal-
ling. The system is robust, simple and efﬁcient and it has the po-
tential to be translated as it can be incorporated (e.g. coatings) on
2D and 3D devices and scaffolds.
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